Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said a US Food and Drug Administration inspection of its Unit-IV API manufacturing facility in Andhra Pradesh, India, concluded with zero observations.
The inspection was conducted from Sept. 7 to Sept. 11 at the facility operated by wholly owned subsidiary Apitoria Pharma, according to an Indian bourse filing by the pharma company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.